SEC Company Response from KALA BIO, Inc. (KALA) (CIK 0001479419) (KALA) — Jul 17, 2017
KALA BIO, Inc. (KALA) (CIK 0001479419)
Date: July 17, 2017 · CIK: 0001479419 · Accession: 0001104659-17-045294
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218936
Letter
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
One Bryant Park
New York, NY 10036
July 17, 2017
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Kala Pharmaceuticals, Inc.
Registration Statement on Form S-1
Registration File No. 333-218936
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, the representatives of the several underwriters (the “Representatives”), hereby join in the request of Kala Pharmaceuticals, Inc. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement on Form S-1, as amended, so that it will be declared effective at 4:00 PM, Eastern Daylight Time, on July 19, 2017 or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Wilmer Cutler Pickering Hale and Dorr LLP, may orally request via telephone call that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as the Representatives, wish to advise you that approximately 3,869 copies of the Preliminary Prospectus, dated July 10, 2017 and included in the above-referenced Registration Statement, as amended, were distributed during the period from July 10, 2017 through the date hereof, to prospective underwriters, institutions, dealers and others.
We were advised on July 12, 2017 by the Corporate Financing Department of the Financial Industry Regulatory Authority that it has reviewed the above-referenced proposed offering and that it has determined to raise no objections with respect to the fairness of the terms and arrangements of the offering.
We, the undersigned, as the Representatives, each confirm on behalf of ourselves and the other participating underwriters that we will comply with the requirements of Rule 15c2-8 under
the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issuance.
Very truly yours,
J.P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, NY 10036 July 17, 2017 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Kala Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration File No. 333-218936 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, the representatives of the several underwriters (the “Representatives”), hereby join in the request of Kala Pharmaceuticals, Inc. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement on Form S-1, as amended, so that it will be declared effective at 4:00 PM, Eastern Daylight Time, on July 19, 2017 or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Wilmer Cutler Pickering Hale and Dorr LLP, may orally request via telephone call that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as the Representatives, wish to advise you that approximately 3,869 copies of the Preliminary Prospectus, dated July 10, 2017 and included in the above-referenced Registration Statement, as amended, were distributed during the period from July 10, 2017 through the date hereof, to prospective underwriters, institutions, dealers and others. We were advised on July 12, 2017 by the Corporate Financing Department of the Financial Industry Regulatory Authority that it has reviewed the above-referenced proposed offering and that it has determined to raise no objections with respect to the fairness of the terms and arrangements of the offering. We, the undersigned, as the Representatives, each confirm on behalf of ourselves and the other participating underwriters that we will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issuance. Very truly yours, J.P. MORGAN SECURITIES LLC MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED By: J.P. MORGAN SECURITIES LLC By: /s/ Phil Ross Name: Phil Ross Title: Managing Director By: MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED By: /s/ Michele A.H. Allong Name: Michele A.H. Allong Title: Authorized Signatory